MRK 241227 99.00P (MRK241227P99000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

MRK241227P99000

Watchlist

0.01
0.000.00%

15min DelayClose Dec 27 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Cramer on Merck & Co. (MRK): Trading Like a Value Trap Despite Strong Fundamentals
Yahoo FinanceJan 10 16:56 ET
Weekly Buzz: CES Came and Brought the Pain? That's Unexpected
Kevin TraversJan 10 16:21 ET
Wall Street Today: Labor Gains Hurt a Hurting Market
Kevin TraversJan 10 16:08 ET
First Earnings Show Beats are Back, December Jobs Climbed but Market Falls Friday | Live Stock
Kevin TraversJan 10 11:16 ET
Atropos Health Collaborates With Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments
BusinesswireJan 10 09:00 ET
IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma
MT NewswiresJan 9 16:24 ET

Comments

luozn

Dec 26, 2024 03:52

$Merck & Co (MRK.US)$ I got high hope on you

Share Your Profit/Loss

Cow Moo-ney

Dec 18, 2024 19:18

Here comes the hawkish cut

Wall Street closed in a sea of red on Wall Street after the Fed cut interest rates by 25 basis points and projected fewer interest rate cuts for 2025 amid sticky and stubborn inflation. This is the “hawkish cut” that many have talked about.
The Dow Jones has declined for 10 straight days, its worst run of consecutive red days since 1974.
It seems that the last path of the Fed's push to bring inflation down to its 2% target is proving more difficult than many have init...

https://youtu.be/S9qnN1rRUyo

From YouTube

Can the Santa Claus rally happen after the Fed's hawkish cut?

Stock_Drift

Dec 18, 2024 05:58

$Merck & Co (MRK.US)$

Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

Stock_Drift

Dec 17, 2024 05:52

$Merck & Co (MRK.US)$

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...